Ethnic Aspects of Valproic Acid P-Oxidation-Reference-Cited by-同舟云学术

Ethnic Aspects of Valproic Acid P-Oxidation

Published:2024-05-08 Issue:5 Volume:12 Page:1036
ISSN:2227-9059
Container-title:Biomedicines
language:en
Short-container-title:Biomedicines

Author:

Shnayder Natalia A.¹²^ORCID,Grechkina Violetta V.¹^ORCID,Trefilova Vera V.¹,Kissin Mikhail Ya.³,Narodova Ekaterina A.²^ORCID,Petrova Marina M.²^ORCID,Al-Zamil Mustafa⁴^ORCID,Garganeeva Natalia P.⁵^ORCID,Nasyrova Regina F.¹⁶

Affiliation:

1. Institute of Personalized Psychiatry and Neurology, Shared Core Facilities, V.M. Bekhterev National Medical Research Centre for Psychiatry and Neurology, 192019 Saint Petersburg, Russia

2. Shared Core Facilities “Molecular and Cell Technologies”, V.F. Voino-Yasenetsky Krasnoyarsk State Medical University, 660022 Krasnoyarsk, Russia

3. Department of Psychiatry and Addiction, I.P. Pavlov First St. Petersburg State Medical University, 197022 Saint Petersburg, Russia

4. Department of Physiotherapy, Faculty of Continuing Medical Education, Peoples’ Friendship University of Russia, 117198 Moscow, Russia

5. Department of General Medical Practice and Outpatient Therapy, Siberian State Medical University, 634050 Tomsk, Russia

6. International Centre for Education and Research in Neuropsychiatry, Samara State Medical University, 443016 Samara, Russia

Abstract

The safety of the use of psychotropic drugs, widely used in neurological and psychiatric practice, is an urgent problem in personalized medicine. This narrative review demonstrated the variability in allelic frequencies of low-functioning and non-functional single nucleotide variants in genes encoding key isoenzymes of valproic acid P-oxidation in the liver across different ethnic/racial groups. The sensitivity and specificity of pharmacogenetic testing panels for predicting the rate of metabolism of valproic acid by P-oxidation can be increased by prioritizing the inclusion of the most common risk allele characteristic of a particular population (country).

Publisher

MDPI AG

Link

https://www.mdpi.com/2227-9059/12/5/1036/pdf

Reference123 articles.

1. Shnayder, N.A., Grechkina, V.V., Khasanova, A.K., Bochanova, E.N., Dontceva, E.A., Petrova, M.M., Asadullin, A.R., Shipulin, G.A., Altynbekov, K.S., and Al-Zamil, M. (2023). Therapeutic and toxic effects of valproic acid metabolites. Metabolites, 13.

2. Shnayder, N.A., Grechkina, V.V., Trefilova, V.V., Efremov, I.S., Dontceva, E.A., Narodova, E.A., Petrova, M.M., Soloveva, I.A., Tepnadze, L.E., and Reznichenko, P.A. (2023). Valproate-induced metabolic syndrome. Biomedicines, 11.

3. Nasyrova, R.F., Ivanov, M.V., and Neznanov, N.G. (2015). Introduction to Psychopharmacogenetics, Publishing Center of V.M. Bekhterev.

4. A comprehensive review on pharmacological applications and drug-induced toxicity of valproic acid;Safdar;Saudi Pharm. J.,2023

5. Chronic valproic acid intoxication in epileptology: Diagnosis and treatment;Shnaider;Neurol. Neuropsychiatry Psychosom.,2016